Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Update

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 300 shares, a drop of 99.8% from the March 31st total of 134,100 shares. Based on an average trading volume of 10,500 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Pieris Pharmaceuticals in a report on Sunday. They set a “hold” rating for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. CM Management LLC boosted its holdings in Pieris Pharmaceuticals by 18.1% in the 3rd quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 99,400 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Pieris Pharmaceuticals by 64.8% during the 3rd quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock valued at $286,000 after buying an additional 378,339 shares during the period. Finally, Summit Trail Advisors LLC purchased a new stake in shares of Pieris Pharmaceuticals during the 1st quarter valued at approximately $26,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Pieris Pharmaceuticals Trading Down 2.8 %

PIRS stock traded down $0.33 during mid-day trading on Thursday, reaching $11.60. The company’s stock had a trading volume of 28,382 shares, compared to its average volume of 9,493. The company’s 50 day moving average is $13.86 and its two-hundred day moving average is $15.45. Pieris Pharmaceuticals has a fifty-two week low of $10.89 and a fifty-two week high of $80.80. The stock has a market cap of $14.38 million, a PE ratio of -0.52 and a beta of 0.48.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($4.00) EPS for the quarter. The company had revenue of $1.30 million during the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative return on equity of 90.17%.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.